Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study
Marcus Maurer, Ana M. Giménez‐Arnau, Silvia Mariel Ferrucci, Vincent Mikol, I. L. Sun, Leda Mannent, Jessica Gereige
Topics & Concepts
Dose-ranging studyMedicineRangingPhase (matter)Internal medicineGeographyPathologyPhysicsAlternative medicineGeodesyDouble blindQuantum mechanicsPlaceboUrticaria and Related ConditionsAutoimmune Bullous Skin DiseasesChronic Lymphocytic Leukemia Research